adamantane has been researched along with Diabetes Mellitus Type 1.5 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H; Li, X; Niu, X; Pei, X; Wang, X; Wu, C; Yan, X; Zeng, X; Zhang, Z; Zhou, Z | 1 |
| Buzzetti, R; Frederich, R; Hirshberg, B; Iqbal, N; Pozzilli, P | 1 |
2 trial(s) available for adamantane and Diabetes Mellitus Type 1.5
| Article | Year |
|---|---|
Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study.
Topics: Adamantane; Adolescent; Adult; Aged; Cholecalciferol; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Insulin-Secreting Cells; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Prognosis; Vitamin D Deficiency; Vitamins; Young Adult | 2020 |
Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose Intolerance; Humans; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Young Adult | 2016 |